https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/ · Data v1.0.1, 17 November 2026
NVIDIA – Recursion Pharmaceuticals
- Investment and partnership
- Related deal
- AI layer: foundation models
- Buyer worth over US$100 billion
- United States
The deal in brief
Showing facts with an official source only.
Recursion Pharmaceuticals works on foundation models for biology and drug discovery.
NVIDIA and Recursion Pharmaceuticals agreed an investment and partnership (opens in a new tab).
NVIDIA invested US$50 million (opens in a new tab) in Recursion Pharmaceuticals.
Why it stands out
- NVIDIA also has a deal with Anthropic (2025) and a deal with OpenAI (2026), in the same AI layer (foundation models).NVIDIA – AnthropicNVIDIA – OpenAI
Key facts
- Announced
- 12 July 2023
- Value
- US$50 million
In the source’s words
“NVIDIA invested $50 million in Recursion via a private placement”
“to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery”
What the buyer received
No public record of: licence, exclusive licence, board seat, observer, veto, exclusivity, right of first refusal, consultation, compute commitment.
Deals with the same termsAbout Recursion Pharmaceuticals
- What it does
- Foundation models for biology and drug discovery.
- Country
- United States
One amount, as the source states it
- US$50 millionInvestment, single private placement“NVIDIA invested $50 million in Recursion via a private placement”Read it in context (opens in a new tab)
Regulators and advisers
Notification thresholds at the time
- HSR general size tests: Holdings valued above USD 111.4m are subject to the size-of-person test through USD 445.5m. One person must generally have USD 22.3m and the other USD 222.7m in annual net sales or total assets under the statutory tests. Above USD 445.5m the size-of-person test drops out. Exemptions and commerce rules remain relevant. Source (opens in a new tab)
Advisers
- Latham & Watkins, legal counsel to NVIDIA
10 sources, grouped by what they prove
The deal terms (3)
- RecursionA · Official source29 February 2024
“priority access”
- RecursionA · Official source12 July 2023
“to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery”
- RecursionA · Official source29 February 2024
“NVIDIA invested $50 million in Recursion”
Money (3)
- RecursionA · Official source12 July 2023
“$50 million investment by NVIDIA”
- RecursionA · Official source
“NVIDIA invested $50 million in Recursion via a private placement”
- Latham & WatkinsA · Official source12 July 2023
“Latham & Watkins Advises NVIDIA on Investment in Recursion Pharmaceuticals”
Read it in context (opens in a new tab)Checked 16 Nov 2026
Dates (1)
- RecursionA · Official source12 July 2023
“July 12, 2023 at 8:30 AM EDT”
Background checks (3): identity, address, headquarters and AI-business test
- SECA · Official source
“"city":"SANTA CLARA","stateOrCountry":"CA"”
- RecursionA · Official source29 February 2024
“Salt Lake City, Utah”
- NVIDIA Corporation (Form 10-K cover page)A · Official source29 July 2022
Form 10-K, aggregate market value held by non-affiliates
“as of July 29, 2022 was approximately $434.37 billion”
Read it in context (opens in a new tab)Checked 16 Nov 2026
Similar deals
NVIDIA’s other deals
NVIDIA and Emerald AI, Inc. agreed an investment and partnership.
NVIDIA invested. Lancium’s AI factory campuses were designated as deployment sites for NVIDIA’s full-stack computing platform.
ContinuedNVIDIA combined investment with access to Rubin systems.
ContinuedOther deals with the same structure
ASML and Mistral AI agreed an investment and partnership.
ContinuedKDDI and Sakana AI agreed an investment and partnership.
ContinuedAlibaba disclosed a minority preferred stake.
Alibaba invested about US$800 million in Moonshot AI.
Cite and download
APA
Boyton, J. (2026). NVIDIA – Recursion Pharmaceuticals (2023). In The Hidden Acquisitions Index (Version 1.0.1). Acquiry Labs. https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/ (checked 2026-11-16)
BibTeX
@misc{hai_nvidia_recursion_2023,
author = {Boyton, Joash},
title = {NVIDIA – Recursion Pharmaceuticals (2023)},
howpublished = {The Hidden Acquisitions Index, Acquiry Labs},
version = {1.0.1},
year = {2026},
url = {https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/},
note = {Checked 2026-11-16}
}Bluebook
Joash Boyton, NVIDIA – Recursion Pharmaceuticals (2023), The Hidden Acquisitions Index (Acquiry Labs, version 1.0.1, 2026), https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/ (last visited 16 November 2026).
Plain text
NVIDIA – Recursion Pharmaceuticals (2023). The Hidden Acquisitions Index, Acquiry Labs, version 1.0.1. https://www.acquiry.com/labs/hidden-acquisitions/deals/nvidia-recursion-2023/. Checked 2026-11-16.
Short attribution
according to the Hidden Acquisitions Index (Acquiry Labs)
- This deal as CSV
- This deal as JSON
- Share card 1200×630
- Share card 1:1
- Share card 4:5
- Share card 16:9
- Journalist pack (zip)
The journalist pack has this deal as CSV, the share card in four sizes, every source with its quote, and a note on how to credit it.
Announced 12 July 2023 · Sources checked 16 Nov 2026 · Data v1.0.1